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Objective: The aim of this study was to compare the effects of medium light roast (MLR) and
medium roast (MR) paper-ﬁltered coffee on cardiovascular risk factors in healthy volunteers.
Methods: This randomized crossover trial compared the effects of consuming three or four cups
(150 mL) of MLR or MR coffee per day for 4 wk in 20 healthy volunteers. Plasma lipids, lip-
oprotein(a) (Lp[a]), total homocysteine, and endothelial dysfunction–related inﬂammation
biomarkers, serum glycemic biomarkers, and blood pressure were measured at baseline and after
each intervention.
Results: Both roasts increased plasma total cholesterol, low-density lipoprotein-cholesterol, and
soluble vascular cell adhesion molecule-1 (sVCAM-1) concentrations (10%, 12%, and 18% for MLR;
12%, 14%, and 14% for MR, respectively) (P < 0.05). MR also increased high-density lipoportein-
cholesterol concentration by 7% (P ¼ 0.003). Plasma ﬁbrinogen concentration increased 8% after
MR intake (P ¼ 0.01), and soluble E-selectin increased 12% after MLR intake (P ¼ 0.02). No changes
were observed for Lp(a), total homocysteine, glycemic biomarkers, and blood pressure.
Conclusion: Moderate paper-ﬁltered coffee consumption may have an undesirable effect on plasma
cholesterol and inﬂammation biomarkers in healthy individuals regardless of its antioxidant
content.
 2013 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Dyslipidemia, hypertension, diabetes or glucose intolerance,
and obesity are associated with a marked increase in vascular
reactive oxygen species (ROS) production, which play important
roles in atherosclerosis, diabetes, and cardiovascular diseases
(CVD). It should be highlighted that ROS are involved in endo-
thelial dysfunction, monocyte migration, low-density lipopro-
tein-cholesterol (LDL-C) oxidation, and vascular smooth muscle
cell growth. ROS induce the expression of vascular cell adhesionn, analysis, and interpre-
ed to study design, data
buted to the study design
tudy design, data analysis,
ﬁnal manuscript and none
: 55-11-3061-7130.
.
evier OA license.molecule-1 (VCAM-1) and monocyte chemoattractant protein-1
(MCP-1) on the endothelial cell surface.
Coffee is consumed as a beverage worldwide; however, its
effect as a cardiovascular risk factor is still controversial [1–3].
Roasted coffee contains naturally present antioxidants and others
that are formed during the roasting process [4]. Chlorogenic acids
(CGA) and caffeine have been extensively studied because they
may play a role in the inhibition of lipid peroxidation, free radical
scavenging,metal chelation, and anti-inﬂammatory activity. They
also may reduce the risk for development and progression of
atherosclerosis [5] and insulin resistance [6,7], and they may
decrease blood pressure (BP) [8,9]. Coffee contains diterpenes,
cafestol, and kahweol, which have a cholesterol-raising effect.
However, most of them are retained by the paper ﬁlter, which
substantially reduces the cholesterol-raising effects potentially
associated with coffee [10,11].
Epidemiologic studies have indicated that regular coffee
consumption is associated with a lower risk for CVD [3,12,13].
However, the coffee compounds responsible for the suggestive
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effect of coffee on inﬂammation are conﬂicting, showing that
coffee consumption by healthy individuals can be either directly
[14], inversely [4], or not associated with proinﬂammatory
biomarkers [15]. Therefore, we compared the effects of ingesting
medium light roast (MLR) ormedium roast (MR) ﬁltered coffee in
plasma lipids, total homocysteine (tHcy), endothelial dysfunc-
tion–related inﬂammation biomarkers, glycemic biomarkers, and
BP in healthy volunteers.
Participants and methods
Participants
Twenty-two healthy and habitual coffee drinkers were recruited and gave
informed consent. This study was approved by the School of Public Health of
S~ao Paulo University Review Board and registered as a clinical trial
(ACTRN12609001064291). Eligibility criteria were age 20 y to 65 y, plasma
cholesterol <6.21 mmol/L, blood glucose <5.56 mmol/L, nonsmoker or former
smoker (>2 y), alcohol consumption less than one drink per day, absence of
chronic diseases, and no use of regular medication. Two subjects declined
participation, one could not attend themeetings, and one consumed coffee during
the washout period. Twenty healthy participants (14 women) were evaluated
(Fig. 1).
Study design
This randomized, crossover clinical trial lasted 9 wk. After a 1-week run-in,
participants consumed MLR or MR paper-ﬁltered coffee for 4 wk and then
switched to the other roast for an additional 4 wk.
Participants were asked to make no changes in their diet or lifestyle. We
questioned physical activity of the participants in the baseline interviewand after
each intervention period. A 3-d food diary (2 d during the week and 1 d on the
weekend) was collected before baseline and during each intervention to control
for possible confounding factors and check for compliance with dietary
instructions.
Coffee samples and beverage preparation
Two commercially available blends (80% Coffea arabica L. cv. Bourbon and
20% C. canephora cv. Robusta) of caffeinated, roasted, ground coffee were used in
the study. Both coffees were cultivated in the same geographic region. They were
vacuum packed in 500-g aluminized bags. Roasting degree classiﬁcation was
done according to the “Roast Color Classiﬁcation System” (Agtron/SCAA, Reno,
NV, 1995). Coffee packages and paper ﬁlters (Classic n 102) were provided by
Melitta do Brasil Industria e Comercio Ltda, S~ao Paulo, Brazil. Coffee was
distributed to participants in 500-g packages at the beginning of each inter-
vention period. Subjects were instructed on how to prepare the beverage (15 g of
coffee/150mL cup) in a household coffee maker by ﬁltering through paper, and to
consume the total daily amount in three of four separate cups without a ﬁxed
schedule.
Coffee beverages were prepared as instructed to the participants for the
analysis of the antioxidant content and diterpenes. CGA and caffeine were
determined by high-performance liquid chromatography (HPLC) with diode-
array detector (DAD) and mass spectrometer [16]. Cafestol and kahweol were
determined in the unsaponiﬁed matter by HPLC with DAD [17].
Blood collection and biomarker assessment
At baseline, and at the end of each intervention, venous blood samples were
taken after a 12-h overnight fast and centrifuged for plasma separation. Plasma
samples were stored at 80C for inﬂammation biomarker analyses.
Plasma concentrations of total cholesterol (TC), high-density lipoprotein-
cholesterol (HDL-C), and triacylglycerol were measured by enzymatic assays on
a Dimension RXL (Siemens Healthcare Diagnostics Deerﬁeld, IL, USA). LDL-C was
calculated according to the Friedewald formula [18]. Plasma lipoprotein(a) (Lp[a])
concentration was assessed by immunonephelometric assay on a BN II analyzer
(Siemens Healthcare Diagnostics, Marburg, Germany). Plasma tHcy concentra-
tion was measured by a chemiluminescence immunoassay on an Immulite 2000
Analyzer (Diagnostic Products Corporation, Los Angeles, CA, USA).
Fasting serum glucose concentration was determined by a commercial kit
(Siemens Healthcare Diagnostics, Marburg, Germany). Blood-glycated hemo-
globin and frutosamine were measured by immunoturbidimetric and colori-
metric assays, respectively. Fasting serum insulin concentration was determined
by a chemiluminescence assay. These analyses were performed by use of an
automated analyzer (Dimension RXL, Siemens Healthcare Diagnostics, Llanberis,Gwynedd, UK). Insulin resistance was estimated by Homeostasis Model Assess-
ment for insulin resistance [19,20].
Plasma ﬁbrinogen concentrations were measured by the Clauss method [21]
on a Destiny Max (MedLab) and high-sensitivity C-reactive protein (hs-CRP)
concentration by use of a high-sensitivity latex-enhanced immunonephelo-
metric assay on BN II analyzer (Siemens Diagnostics). Interleukin (IL)-1b, IL-6,
tumor necrosis factor (TNF)-a, MCP-1, soluble E-selectin (sE-selectin), sVCAM-
1, soluble intercellular adhesion molecule-1 (sICAM-1), and tissue-type plas-
minogen activator inhibitor-1 (PAI-1) were quantiﬁed by bead-based multiplex
Luminex xMAP technology assays (Millipore, Missouri, USA) on a Luminex
200 analyzer (Luminex Corporation, Austin, TX, USA).
Assessment of other measurements
Weight, height, abdominal circumference, and body fat were measured after
the washout period and after each intervention. Body mass index (BMI) was
calculated as weight (kg) divided by height (m2). Body fat percentage was
measured by bipolar impedance on a portable electronic scale (Plenna, S~ao Paulo,
Brazil).
BP was measured by ambulatory BP monitoring, using a 90207 portable
monitor (Spacelabs Healthcare, Washington, USA), scheduled for six measure-
ments during the day (between 0700 and 2200) and three at night (between
2200 and 0700).
Statistical analysis
The results are expressed as means  SD. CGA, caffeine, and diterpenes
content of the two coffee beverages were compared by t test for independent
samples. Differences in biomarker concentrations were analyzed by paired t test
(glucose biomarkers) or by repeated-measures analysis of variance (ANOVA) for
comparisons of MLR coffee intake with MR and of each roast with the baseline.
Variables that were not normally distributed (Lp[a], fasting glucose, diastolic BP
and heart rate) were submitted to the logarithmic transformation and analyzed
by repeated-measures ANOVA. Evaluation of the two groups’ mean proﬁle was
carried out to measure the effects of the MLR and MR order of consumption and
possible carryover effect. All analyses were performed using SPSS 18.0 (SPSS Inc.,
Chicago, IL, USA). A two-tailed P < 0.05 was considered signiﬁcant.
Results
Participants
Twenty healthy individuals (49  9 y, range 37–63 y) were
evaluated. Table 1 shows their baseline characteristics. Most
participants were women (70%) and overweight (76%).
During the ﬁrst 4-wk intervention period, 45% of the partic-
ipants (55.6% women) ingested MLR coffee and 55% (81.8%
women) MR coffee. In the next 4-wk period, they switched to the
opposite roast coffee. Coffee consumption was 482  61 mL/d
throughout the study. Coffee provided 334 mg of CGA per cup in
MLR and 210 mg per cup in MR (P < 0.001) and 231 mg of
caffeine per cup in MLR and 244 mg per cup in MR (P ¼ 0.003).
The mean concentrations of cafestol and kahweol were 5.36 mg
and 0.79 mg per cup in MLR and 6.30 mg and 0.51 mg per cup in
MR, respectively. MLR provided more CGA and kahweol and less
caffeine, cafestol, and melanoidins (P < 0.001) than MR.
Self-reported diets showed that none of the participants
consumed a signiﬁcant amount of polyphenol-rich foods other
than coffee during the study and the nutritional intake was
similar before and after each intervention period for all partici-
pants (P > 0.05). Additionally, we found no signiﬁcant differ-
ences in physical activity, body composition, and BP throughout
the study (data not shown).
Cardiovascular risk biomarkers
Table 2 shows a signiﬁcant increase in TC and LDL-C after
intake of each coffee roast compared with the baseline. TC
concentrations increased 0.46 mmol/L after MLR (P < 0.01) and
0.59 mmol/L after MR (P < 0.001). LDL-C increased 0.36 mmol/L
ABPM, ambulatory blood pressure monitoring
Volunteers visited the Heart Institute (InCor), University of São Paulo Medical 
School, after receiving invites from former participants of the study, hospital staff, 
and relatives who are treated in the hospital or watched study information 
published on TV or the Internet.
Biochemical exams; clinical and nutritional evaluation
Participants included in the study (N = 22)
Losses (n = 2)
1 subject could not attend the meetings and 
1 consumed coffee during the run-in period.
Intervention - 8 wk (N = 20) 
Baseline
- Clinical and nutritional evaluation
- Blood samples
- ABPM
Run-in
1 wk
Medium light roast
n = 9
Medium roast
n = 11
After 4 wk
- Clinical and nutritional evaluation
- Blood samples
- ABPM
Medium roast
n = 9
Medium light roast 
n = 11
After 4 wk
- Clinical and nutritional evaluation
- Blood samples
- ABPM
Fig. 1. Flowchart of the study. The ﬂowchart shows a randomized crossover clinical trial.
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respectively. HDL-C increased 0.09 mmol/L after MR intake
(P < 0.01). We observed no difference in TC and LDL-C between
the two intervention periods. However, there was an increase
of 0.04 mmol/L in HDL-C after MR intake in relation to MLR
(P¼ 0.04). Plasma triacylglycerols increased, but not signiﬁcantly.
No signiﬁcant effect of the two coffee roasts was observed on
plasma Lp(a), tHcy, or serum glycemic biomarkers (data not
shown).
We observed an 8% increase in plasma ﬁbrinogen concen-
tration after MR intake (P < 0.01) and 12% in sE-selectin after
consumption of MLR (P < 0.05). Fibrinogen increased after MLRand sE-selectin increased after MR, but these were not signiﬁ-
cant. Fibrinogen concentration also increased 6.5% after MR in
relation to MLR (P ¼ 0.02). Plasma sVCAM-1 increased 18% and
14% after MLR (P < 0.001) and MR (P < 0.05), respectively
(Table 2). No signiﬁcant changes were found for hs-CRP, IL-1b,
IL-6, TNF-a, MCP-1, sICAM-1, and tPAI-1.
Discussion
We observed an increase in HDL-C after MR consumption,
which is of great relevance, as this particle has been recognized
as an anti-atherogenic. Some proposed mechanisms for this
Table 1
Baseline characteristics of the participants (N ¼ 20)
Gender (male/female, n) 6/14
Age (y) 49.5  8.9
BMI (kg/m2) 27.0  3.8
Body fat (male/female, %) 29.1  3.0/37.5  4.2
Abdominal circumference (male/female, cm) 98.7  4.9/92.8 9.0
Lipoprotein(a) (mg/dL) 21.6  26.5
Total homocysteine (mmol/L) 9.2  3.0
Fasting glucose (mmol/L) 4.8  0.6
Glycated hemoglobin (%) 5.5  0.3
Frutosamine (mmol/L) 226.6  12.7
Fasting insulin (mU/mL) 3.6  3.4
HOMA-IR 0.8  0.8
24-h blood pressure averages (mm Hg)
Systolic 110.2  9.7
Diastolic 70.5  6.9
24-h heart rate averages (beats/min) 77.2  10.1
Habitual coffee consumption (mL/d) 307  110
Energy intake (kcal/d) 1831  535
Carbohydrate (% energy) 52.2  9.2
Protein (% energy) 19.9  6.3
Total fat (% energy) 27.8  8.5.9
Cholesterol (mg/d) 157.3  71
Family history of CVDs (%) 30
BMI, body mass index; CVD, cardiovascular disease; HOMA-IR, Homeostasis
Model Assessment for insulin resistance
Data expressed as mean  standard deviation, numbers or %
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LDL-C oxidation, blood viscosity reduction, regulation of pros-
taglandins and thromboxane synthesis, activation of ﬁbrinolysis,
inhibition of adhesionmolecules andmonocytes to endothelium,
and stimulation of nitric oxide release [22].
TC and LDL-C concentrations increased after consumption of
each coffee roast comparedwith baseline. However, therewas no
signiﬁcant change in these lipids between the coffee roasts,
indicating that the roasting degree is not related to an increase in
these lipid concentrations. Data on the effects of ﬁltered coffeeTable 2
Lipid proﬁle and inﬂammation biomarkers at baseline and after intake of each
roast of ﬁltered coffee
Biomarkers Baseline MLR MR
Lipids
TC (mmol/L) 4.8  0.6 5.3  0.9* 5.4  0.8y
HDL-C (mmol/L) 1.2  0.3 1.3  0.3 1.3  0.2*,x
LDL-C (mmol/L) 3.1  0.5 3.4  0.7* 3.5  0.7y
Triacilglycerols (mmol/L) 1.1  0.4 1.2  0.5 1.2  0.6
Inﬂammation biomarkers
Fibrinogen (mg/dL) 357.1  48.3 362.3  67.8 385.8  67.7*,x
sE-selectin (pg/mL) 33.6  11.9 37.7  14.8z 34.4  11.6
sVCAM-1 (pg/mL) 1049  174 1235  256y 1191  299z
hs-CRP (mg/L) 2.2  2.1 2.1  2.0 2.6  2.2
IL-1b (pg/mL) 0.1  0.2 0.1  0.1 0.1  0.2
IL-6 (pg/mL) 1.2  0.8 1.7  2.6 1.3  1.2
TNF-a (pg/mL) 2.8  1.4 3.3  2.4 2.9  2.0
MCP-1 (pg/mL) 75.4  19.3 79.6  15.7 80.1  17.9
sICAM-1 (pg/mL) 220.5  62.5 243.1  91.7 237.6  85.9
tPAI-1 (pg/mL) 54.6  20.3 53.8  20.1 54.1  21.4
ANOVA, analysis of variance; hs-CRP, high-sensitivity C-reactive protein; IL-1b,
interleukin-1 beta; IL-6, interleukin-6; LDL-C, low-density lipoprotein-
cholesterol; HDL-C, high-density lipoprotein-cholesterol; MCP-1, monocyte
chemoattractant protein-1; MLR, medium light roast; MR, medium roast; sICAM-
1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell
adhesion molecule-1; TC, total cholesterol; TNF-a, tumor necrosis factor-alpha;
tPAI-1, total plasminogen activator inhibitor-1
Data expressed as means  SD (n ¼ 20).
* Signiﬁcantly different from baseline (ANOVA of repeatedmeasures): P< 0.01.
y Signiﬁcantly different from baseline (ANOVA of repeated measures):
P < 0.001.
z Signiﬁcantly different from baseline (ANOVA of repeatedmeasures): P< 0.05.
x Signiﬁcantly different from MLR (ANOVA of repeated measures): P < 0.05.intake on plasma lipids are still limited and contradictory [23].
Increased plasma TC and LDL-C are more pronounced with
unﬁltered coffee, whereas paper-ﬁltered coffee has been less
frequently reported to raise these lipids [6].
Cafestol levels obtained in this study were higher than those
found for the paper-ﬁltered coffee in other studies [17,24,25],
which might explain the increase of plasma cholesterol
concentrations observed. These ﬁndings are in agreement with
studies that showed that diterpenes are only partly removed by
the paper ﬁlter [10,11]. Several variables may inﬂuence the
diterpenes content in the paper-ﬁltered coffee such as coffee
species, geographical distribution, roasting degree, grind sizes,
extraction time and temperature, porosity of the paper ﬁlter, and
coffee-to-water ratio [25,26]. An interesting fact that should be
mentioned is that we did not ﬁnd signiﬁcant increase in tri-
acylglycerols concentration, a cafestol consumption-related
effect observed in some studies [25,27,28].
Cafestol has been reported to be the most potent cholesterol-
raising compound of a coffee brew. The mechanism for the effect
of cafestol on the increase of plasma cholesterol concentration
remains unclear. However, Ricketts et al. [29] proposed a mech-
anism that could explain this effect. “Cafestol activates the
nuclear hormone receptors pregnane X receptor (PXR) and far-
nesoid X receptor (FXR) in the small intestine. Then, PXR acti-
vates Cyp27A1 and ABCA1 expression, increasing the efﬂux of
cholesterol to the liver. FXR activates the intestinal bile acid-
binding protein (IBABP), a bile acid transporter, increasing the
transportation of bile acids into the portal circulation. Both PXR
and FXR induce ﬁbroblast growth factor 15 (FGF15), which
signals to the liver to inhibit bile acids synthesis. In the liver, FXR
suppress the expression of Cyp7A1, Cyp8B1, and NTCP, reducing
the synthesis of bile acids, increasing consequently the choles-
terol concentrations.”
Previous studies [11,27] found signiﬁcant increases in TC and
LDL-C, but not in HDL-C, after coffee consumption. A few studies
found a positive association between ﬁltered coffee consumption
and an increase in HDL-C concentration [4,30], as we did, which
can counterbalance the deleterious effects of increased LDL-C.
We observed no signiﬁcant change in glycemic biomarkers
after the intervention periods. Another interventional trial [4]
also observed no signiﬁcant changes in these biomarkers after
ﬁltered coffee intake.
We observed a signiﬁcant increase in plasma ﬁbrinogen
concentration after MR consumption. We also observed an
increase in sE-selectin after MLR, and in sVCAM-1 after intake of
each coffee roast, which suggests an inﬂammatory effect related
to coffee consumption.
Several studies suggest that oxidized LDL stimulates the
expression of adhesionmolecules in endothelial cell surface [31].
However, in another study [32], we observed no signiﬁcant
changes in oxidized LDL after consumption of both coffee roasts.
Fibrinogen concentration and adhesion molecule expression are
positively correlated with TNF-a, hs-CRP, BMI, BP, and blood
glucose [31,33]; however, these parameters did not change
signiﬁcantly in this study. To date, data on the relationship of
coffee consumption and inﬂammation biomarkers are scarce and
contrasting. One study found an increase [14] in inﬂammation
biomarkers after coffee consumption for healthy individuals.
Other studies have found no signiﬁcant changes for the inﬂam-
mation biomarkers evaluated in our study [4,15]. Coffee
components responsible for the increase of these biomarkers are
still unknown [4].
We observed no signiﬁcant difference in lipid proﬁle and
inﬂammation biomarkers between 4 wk and 8 wk of coffee
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that the increase in lipids and inﬂammation biomarker concen-
tration is an acute effect of coffee that is unrelated to a potential
accumulative effect of longer periods of coffee consumption.
Our study has some limitations. First, it comprised a small
sample size, which may be explained by its considerable
participation period (9 wk) and the large coffee intake. Second,
the fact that roasting degrees were similar also might constitute
a limitation, but it should be noted that their antioxidant
composition is different and that HDL and ﬁbrinogen concen-
tration increased only after MR intake and sE-selectin increased
only after MLR intake. Finally, the absence of a run-in period
between the interventions was a potential limitation. However,
the statistical analysis showed that there was no carryover effect.
As strengths, this is the ﬁrst interventional trial to show an
increase in inﬂammation biomarkers of healthy individuals after
coffee consumption and to compare the effects of two different
coffee roasts on inﬂammation. Previous studies of the effect of
coffee on inﬂammation markers were generally observational or
cross-sectional studies [14,15]. One study was an interventional
trial, but the amount of coffee consumed was three times higher
than the amount used in our study and fewer proinﬂammatory
markers were analyzed [4]. Additionally, our study analyzed
several cardiovascular risk biomarkers.
Moderate ﬁltered coffee consumption has undesirable effects
on cholesterol and inﬂammation biomarkers in healthy indi-
viduals, regardless of its antioxidant content. More interven-
tional trials and the evaluation of other coffee components are
needed to clarify its effects on cardiovascular risk factors and to
identify the main players associated with these effects.
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